You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR BELIMUMAB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for belimumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00071487 ↗ Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) Completed Human Genome Sciences Inc. Phase 2 2003-10-01 The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.
NCT00071812 ↗ A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) Completed Human Genome Sciences Inc. Phase 2 2003-12-01 The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with rheumatoid arthritis (RA).
NCT00410384 ↗ A Study of Belimumab in Subjects With Systemic Lupus Erythematosus Completed GlaxoSmithKline Phase 3 2006-12-01 The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
NCT00410384 ↗ A Study of Belimumab in Subjects With Systemic Lupus Erythematosus Completed Human Genome Sciences Inc. Phase 3 2006-12-01 The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for belimumab

Condition Name

Condition Name for belimumab
Intervention Trials
Systemic Lupus Erythematosus 21
Lupus Erythematosus, Systemic 4
Lupus Nephritis 3
Sjögren's Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for belimumab
Intervention Trials
Lupus Erythematosus, Systemic 26
Syndrome 4
Nephritis 3
Sclerosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for belimumab

Trials by Country

Trials by Country for belimumab
Location Trials
United States 263
Germany 40
China 29
Brazil 29
Canada 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for belimumab
Location Trials
New York 17
California 13
Alabama 13
Ohio 13
Texas 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for belimumab

Clinical Trial Phase

Clinical Trial Phase for belimumab
Clinical Trial Phase Trials
Phase 4 6
Phase 3 13
Phase 2/Phase 3 2
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for belimumab
Clinical Trial Phase Trials
Completed 30
Recruiting 14
Not yet recruiting 7
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for belimumab

Sponsor Name

Sponsor Name for belimumab
Sponsor Trials
GlaxoSmithKline 40
Human Genome Sciences Inc. 13
Human Genome Sciences Inc., a GSK Company 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for belimumab
Sponsor Trials
Industry 65
Other 42
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.